Authors
Latest:
Overview of the LAURA StudyPanelists give an overview of the LAURA trial, highlighting its objectives, methodologies, and key findings related to chronic spontaneous urticaria management.
Latest:
Exploring New Therapies and Sequencing in Relapsed CLLNicole Lamanna, MD, discussed some of the ongoing clinical trials evaluating new therapies for patients with chronic lymphocytic leukemia.
Latest:
Navigating Treatment Options for HER2+ BC: A Need for CustomizationAdrienne Waks, MD, discusses the unmet needs in early-stage HER2-positive breast cancer.
Latest:
Final ThoughtsPanelists discuss how final thoughts emphasize the importance of ongoing research, collaborative care, and adapting treatment strategies to improve patient outcomes in the evolving therapy landscape.
Latest:
Telehealth Becomes Mainstream in Oncology PracticesDavid W. Dougherty, MD, MBA, discusses telemedicine in oncology after emergence of COVID-19.
Latest:
Advice for Oncologists and Next Steps for the CLEAR Trial in RCCViktor Grünwald, MD, PhD, discusses what findings from the post hoc analysis of the CLEAR trial of lenvatinib plus pembrolizumab vs sunitinib for patients with renal cell carcinoma mean for community oncologists.
Latest:
Investigators Observe Differences in Toxicity for Sarcoma Due to DosingGary K. Schwartz, MD, discusses adverse events seen in patients with metastatic sarcoma participating in the Alliance A091401 trial.
Latest:
Ongoing Challenges With Trials in the Community Oncology SettingBenjamin Garmezy, MD, discusses some of the ongoing challenges or disparities seen in the community oncologist setting related to clinical trials.
Latest:
Gender-Specific AI Model Advances Understanding of Glioblastoma Progression and Treatment ResponseDistinguishing on current imaging between disease progression and pseudo progression in patients with glioblastoma is one of the most difficult clinical problems, according to Manmeet Ahluwalia, MD and Pallavi Tiwari, PhD.
Latest:
Insights From the AURIGA Trial in Multiple MyelomaAshraf Z. Badros, MB, ChB, discusses the key takeaways from the phase 3 AURIGA trial.
Latest:
Adaptation in Oncology Practice Opens the Door to SpecializationDemands by patients, market pressures, and changing delivery models have brought to the fore the urgency to address whether subspecialization is necessary and entirely feasible.
Latest:
Understanding Extranodal Extension in Head and Neck Cancer: New Imaging Guidelines ExplainedChristina Henson, MD, discusses how new guidelines for head and neck cancer imaging could change dynamics for physicians and patients.
Latest:
Key Takeaways from ASH 2023 in Myelofibrosis and AMLFollowing their review of updates from clinical trials presented at ASH 2023, the Oncology Brothers provide their key takeaways on recent data in myelofibrosis and acute myeloid leukemia.
Latest:
Navigating Unmet Needs in SR/D cGvHDDr Chao provides his insights into the ongoing complexities that clinicians face and shaping a comprehensive understanding of the areas requiring further attention and innovation in cGvHD management.
Latest:
Gynecologic Cancer Awareness Month: Progress Makes Cervical Cancer Highly Treatable, Increasingly PreventableFor Gynecologic Cancer Awareness Month, Dr. Sonal Sura discusses the recent progress in the treatment of patients with cervical cancer.
Latest:
Interpreting the Results of the ELEVATE-TN Trial for Treatment-Naive CLLNakhle Saba, MD, discusses the significance of the key findings of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab for patients with chronic lymphocytic leukemia.
Latest:
How Data Help Physicians Improve Operations and Achieve Health EquityA US health care executive survey found 30% see health equity solely as a social concern. Yet, it's about ensuring everyone has a fair shot at optimal health. Utilizing standardized data can shift care from reactive to preventive, easing strain on systems.
Latest:
Behind the Development of the DCISionRT Test in DCISChirag Shah, MD, discusses the challenges in predicting the risk of local recurrence in patients with ductal carcinoma in situ, and what led to the DCISionRT test.
Latest:
Managing Symptoms of Diarrhea Improves Medication Adherence in Patients Treated With AbemaciclibDose escalation may be beneficial for patients starting treatment regimens with a high incidence of toxicities that may lead to abrupt patient self-discontinuation.
Latest:
Clinical Considerations with Axtilimab in R/R GVHDPanelists discuss how clinical considerations shape the use of axatilimab in relapsed or refractory graft-versus-host disease, addressing factors that influence its application and management in practice.
Latest:
Axi-Cel Demonstrates Efficacy in Non-Hodgkin Lymphoma, Including DLBCLCaron Jacobson, MD, discusses the survival and response data for axicabtagene ciloleucel from the phase 1/2 ZUMA-1 trial.
Latest:
Available Options for the Treatment of EGFR+ Lung CancerEdward B. Garon, MD, MS, provides an overview of some of the available treatment options for patients with EGFR-mutated lung cancer.
Latest:
IL-10 and CXCL10 in Urine May Predict Response to BCG Therapy in Bladder CancerFelix Guerrero-Ramos, PhD, discusses the results from an analysis of IL-10 and CXCL10 in urine as useful biomarkers of response to bacillus Calmette-Guerin in patients with bladder cancer.
Latest:
Optimizing Transplant Timing in Acute Lymphoblastic LeukemiaPartow Kebriaei, MD, discusses when the optimal time for transplant is in patients with acute lymphoblastic leukemia.
Latest:
Novel Treatment Strategies in Endometrial CancerClosing out their program on endometrial carcinoma management, key opinion leaders highlight key novel therapeutic strategies in the evolving treatment landscape.
Latest:
Bladder Cancer Field Leans Towards Patient-Centered CareTracy Rose, MD, discusses the promising outlook of the current bladder cancer space.
Latest:
Exploring Advancements in Higher-Risk MDSDespite recent setbacks in clinical trials, there is still hope for improving treatments for high-risk myelodysplastic syndromes.
Latest:
Pegsitacianine Informs Surgery in Peritoneal CarcinomatosisCurrently, cytoreductive surgery remains a pillar of modern treatment for peritoneal carcinomatosis.
Latest:
Nearly 4 Years Later, Pembrolizumab Plus CRT Shows Staying PowerSalma Jabbour, MD, discusses the implications of a 4-year follow-up of the KEYNOTE-799 study of pembrolizumab and chemoradiotherapy in stage III non–small cell lung cancer.
Latest:
Deep Responses in Multiple Myeloma Seen With Bispecific AntibodyJeffrey Zonder, MD, discusses the efficacy results of a first-in-human trial of a bispecific monoclonal antibody in patients with relapsed/refractory multiple myeloma.
